Abstract
Although multiple myeloma is sensitive to both chemotherapy and RT, it remains incurable at present. However, treatment algorithms based on published data, as well as clinical experience, can be developed to optimize therapy. This includes not only therapy for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.
Publication types
-
Consensus Development Conference
-
Guideline
-
Practice Guideline
-
Review
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Chemotherapy, Adjuvant
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Multiple Myeloma / complications
-
Multiple Myeloma / diagnosis*
-
Multiple Myeloma / therapy*
-
Neoplasm Staging
-
Plasmacytoma / diagnosis
-
Plasmacytoma / therapy
-
Prognosis
-
Radiotherapy, Adjuvant
-
Salvage Therapy
-
Transplantation, Autologous
-
Transplantation, Homologous
-
Treatment Outcome